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Summary
Objective: Cartilage oligomeric matrix protein (COMP) is a component of articular cartilage whose serum levels show a strong correlation
with radiographic osteoarthritis (OA) status. It has recently been found, however, that COMP is also produced in synovium. To assess the
hypothesis that synovitis affects serum COMP levels in patients with knee OA, we collected sera for COMP simultaneous with a clinical
examination for synovitis.
Design: Sera were collected from OA patients who fulfilled the American College of Rheumatology criteria for knee OA. Radiographs were
classified according to the grading system of Kellgren and Lawrence. Synovitis was diagnosed clinically by joint tenderness plus swelling
and/or increased warmth over the joint. COMP levels in sera were measured by inhibition ELISA with monoclonal antibody (mAb) 17-C10.
Results: Serum COMP levels were significantly correlated with age, synovitis and an interaction of synovitis and OA severity. Synovitis
showed the strongest effect on COMP levels (R=0.1587, P<0.01), in contrast to C-reactive protein, duration of OA and OA severity score
which showed no significant effect on COMP levels. Individual signs of synovitis, namely, joint tenderness and warmth had a significant effect
on serum COMP levels while swelling alone did not.
Conclusion: Synovitis exerts a significant effect on serum COMP levels measured with mAb 17-C10 in OA patients. These findings
underscore the importance of the clinical joint examination to assess for synovitis, when attempting to apply objective measures, such as
COMP, to the clinical setting. © 2001 OsteoArthritis Research Society International
Key words: Osteoarthritis, COMP, Serum, Synovitis.Received 18 April 2000; revision requested 28 June 2000;
revision received 15 January 2001; accepted 22 February 2001.
Supported by grants no. 2915-3 (VV, RV), 4887-3 (VV), and
2154-3 (MO, SM, JG, KP) from IGA MZ C{R and NIH
5P60AG11268, NIHAG15108, and Arthritis Foundation Biomedical
Science Grant (VBK).
Address correspondence to: Vladimı´r Vilı´m, Institute of
Rheumatology, Na Slupi 4, 128 50 Prague 2, Czech
Republic. Tel.: (420)-(2)-24915234; Fax: (420)-(2)-24914451;
E-mail: vili@revma.czIntroduction
Cartilage oligomeric matrix protein (COMP) is a member of
the thrombospondin family of extracellular calcium-binding
proteins that was initially isolated from cartilage1. COMP is
a non-collagenous glycoprotein of high molecular weight
(>500 kDa), composed of five identical subunits2. Primary
sequences of rat, mouse, and human COMP have been
determined so far2,3. The carboxy-terminal globular domain
of native COMP binds to collagens I and II4. A five-stranded
coiled-coil domain, formed when subunits assemble their
amino-terminal ends into an oligomer5, may have a storage
and delivery function for hydrophobic cell signaling mol-
ecules such as vitamin D6. The significance of COMP for612normal development and function of cartilage has been
underscored by the discovery that mutations of the COMP
gene result in pseudoachondroplasia and some forms of
multiple epiphyseal dysplasia7.
Osteoarthritis (OA) is a common disease causing pain
and disability in a significant proportion of the adult popu-
lation8. It is characterized by the progressive destruction of
articular cartilage and concomitant changes in subchondral
bone9. A diagnosis of knee OA, traditionally based upon
weight-bearing radiographs and pain, is usually made by
the time tissue destruction is already advanced. Therefore,
much attention has been focused on developing assays for
cartilage derived macromolecules or their fragments whose
release into the circulation from the joint may reflect distur-
bances in joint tissue turnover. Although many unresolved
questions remain10, such ‘markers’ may provide insight into
the early stages of the disease11 as well as facilitating
diagnosis, prognosis and disease severity evaluation12.
COMP has been suggested as a promising candidate
molecular marker of OA13, especially because it has been
shown to be relatively specific to joint tissues.
Most previously published studies reporting serum
COMP levels in OA have concentrated on its use as a
potential prognostic marker; in all these studies COMP has
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PATIENTS
This study was approved by the local research ethics
committee. Patients seen consecutively over a 6-month
period in the outpatient clinic of the Institute of
Rheumatology, Prague, Czech Republic, with knee pain
and who fulfilled the American College of Rheumatology
criteria for knee OA30 were recruited into the study. All
eligible patients (N=196) chose to participate. Blood
was collected for serological studies, and standing antero-
posterior radiographs of both knees were performed.Radiographs of tibiofemoral joints were classified accord-
ing to the grading system of Kellgren and Lawrence
(K–L)31. A single radiologist (JG) scoring the radiographs
was blinded to the results of the clinical exam. Patients
were examined by a single rheumatologist blinded to the
radiographic results, who clinically assessed three signs of
knee joint inflammation, tenderness (T), non-bony swelling
(S), and warmth (W), and graded each sign on a scale of
0–3 according to the method of Thompson32 resulting in
total scores ranging from 0 to 9. Tenderness was assessed
by palpation along the joint-line (capsular/joint-line tender-
ness, which suggested capsular/intracapsular origin of
pain). Swelling was assessed by clinical tests used for
detection of synovial fluid presence (palpation, bulge sign).
Warmth was assessed by the investigator’s palm after
patients accommodated to the local room temperature.
Synovitis of the knee was defined as the presence of joint
tenderness of at least grade 1 plus swelling and/or warmth
of at least grade 1 for the same knee. The reproducibility of
the determination of all three clinical signs of inflammation
and of the presence of clinical synovitis overall was esti-
mated by repeating the examination of 15 patients (30
knees) by the study rheumatologist on two consecutive
days. For particular signs of knee joint inflammation, i.e., T,
S, and W, the reproducibility was 83%, 90%, and 86.7%,
respectively; the intra-observer reproducibility for presence
of clinically diagnosed synovitis was 80%. Patients were
interviewed to obtain a global patient assessment of dis-
ease severity referred to here as the ISK score or ‘Index of
Severity for Knee Osteoarthrosis’33 where higher scores
are indicative of more severe disease. The clinical exami-
nation and blood collection were performed concurrently on
fasting patients instructed to refrain from the use of their
arthritis medications on the morning of the evaluation.IMMUNOASSAYS
Sera were obtained from blood samples collected in
sterile tubes without additives, and stored at −80°C.
C-reactive protein (CRP) levels were measured simul-
taneously by two methods: (a) by immunoturbidi-
metric assay kit commercially available from Boehringer
Mannheim Systems and (b) by sensitive sandwich ELISA
supplied as a kit (UBI MAGIWELL CRP QUANTITATIVE
AD-401) by UBI, Mountain View, CA, U.S.A. CRP levels
determined by both methods were correlated (P<0.0001)
when compared using the Spearman correlation coefficient
(r) (not shown).
COMP was analysed by inhibition ELISA essentially as
previously described26, with several minor modifications.
Briefly, plate coating was performed with coating buffer
(20 mM carbonate/bicarbonate, pH 9.2, 0.002% sodium
azide) containing human articular cartilage COMP at 5 g/
ml. Nunc-Immuno (MaxiSorp) plates (Nunc, Denmark)
were coated with 50 l/well, covered with plate sealing tape
and kept at 4°C until used. COMP standard, purified as
previously described26 from human articular cartilage, was
initially diluted to 1 g/ml. An initial serum dilution of 1:2
was used. Standards as well as samples were further
diluted in PBS-0.05% Tween 20, pH 7.3 (TPBS) in a Nunc
Microwell (low-binding) plate (Nunc, Denmark). Anti-
(human)COMP Mab 17-C1026 was diluted 1:40,000 in
TPBS/1% bovine serum albumin (TPBS/BSA). Primary
antibody (70 l) was added to 70 l of the COMP standard
or patient sera. The inhibition mixtures were incubated at
4°C overnight. A 100 l aliquot of these inhibition mixturesbeen measured by enzyme linked immunosorbent assay
(ELISA) with polyclonal antibodies. Two of these studies
have demonstrated an association of increasing serum
COMP levels with progression of OA monitored radio-
graphically. In the study by Sharif et al.14, serum COMP
increased significantly in patients with clinical knee OA who
showed decreased joint space or required knee surgery
during a five-year follow-up period. Petersson et al.15
determined serum concentrations of COMP over a 3-year
period in individuals with chronic knee pain (with or without
radiographic evidence of knee joint OA at study entry) and
found that COMP levels increased significantly only in the
individuals with radiographic OA at follow-up, while remain-
ing unchanged in the individuals with normal radiographs at
follow-up. Conrozier et al.16 showed that baseline serum
COMP correlated with mean joint space narrowing over 1
year in symptomatic hip OA patients. No correlation has
been found in another study comparing baseline serum
COMP levels to disease progression defined arthroscopi-
cally over a 1-year period17. In addition, serum concen-
trations of COMP, measured in a group of individuals
with chronic knee pain, has correlated positively with the
extent of bone scan abnormalities18.
Taken together, the results of studies performed so far
are promising with regard to COMP as an OA biomarker;
their interpretation however, has been complicated by
recent discoveries that, besides cartilage, COMP is pro-
duced by practically all tissues within a joint, namely
tendon19, ligament and meniscus20, and synovium21–25.
This finding has led some authors to speculate that
synovitis may affect serum COMP level by influencing
synovial tissue synthesis and release of COMP into the
circulation24,25.
We have developed a panel of monoclonal antibodies
(mAbs) to human COMP and we used one of them,
17-C10, to develop a competitive indirect inhibition ELISA
for COMP26. The mAb 17-C10 recognizes a conformational
epitope in a domain of EGF-like repeats27 that is located
near the center of a COMP subunit, and as such it should
be unaffected by partial, N- or C-terminal, cleavage of the
antigen. Like polyclonal antibodies used by other authors
previously, the 17-C10 mAb does not appear to distinguish
between COMP produced by chondrocytes and COMP
produced by synovial fibroblasts28. Our previous studies on
sera have demonstrated that mAb 17-C10 is capable of
distinguishing groups of OA-affected and unaffected (no
radiographic hip or knee OA) subjects, and also subgroups
of OA patients sorted by severity of OA and number of knee
and hip joints involved29. The goal of this study was to
assess the influence of synovitis, a common and important
clinical sign often manifested with OA, on serum COMP
levels.
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Immuno plate and incubated for 60 min at 4°C. The plates
were then washed and received 100 l/well of a solution of
horse radish peroxidase-conjugated rabbit anti-mouse
immunoglobulin antibody, absorbed with human immu-
noglobulins (Dako A/S, Denmark) diluted 1:1000 with
TPBS/BSA. After incubating for 60 min at room tempera-
ture, unbound antibody was removed by washing and
100 l of substrate (o-phenylenediamine plus H2O2) was
placed into the wells for 30–60 min at room temperature.
The production of chromophore was stopped by the
addition of 50 l of 2 M H2SO4. The plates were read at a
wavelength of 490 nm. Results are expressed as equiva-
lents of the standard human antigenic COMP (g/ml). Each
plate contained four identical samples of ‘control’ sera
which were kept aliquoted and frozen at −70°C. Each day
a fresh aliquot of these control samples was thawed and
used on every plate to calculate intra- and interassay
variance of the assay34. We found intra- and interassay
variance of the assay to be less than 4% and less than 5%,
respectively. Analyses were performed without knowledge
of the clinical data.STATISTICAL METHODS
Geometric means and their 95% confidence inter-
vals (95% CI) were calculated. Differences between
ln-transformed serum COMP levels [ln(COMP)] in groups
of patients sorted according to K–L grade and synovitis
were assessed by two-way ANOVA. Natural logarithm
transformation of serum COMP levels was done in order to
satisfy the assumptions of a Gaussian distribution of the
data underlying the use of ANOVA methods. To describe
dependency of ln(COMP) on age and gender and to test for
an effect of other factors on ln(COMP) we used multiple
linear regression. From each of the models, regression
coefficients and their 95% confidence intervals were calcu-
lated. Linear regression model was also used for adjusting
the geometric mean to the mean age. Scores of three
clinical signs of knee joint inflammation (T+S+W) were
compared to CRP levels using the Spearman correlation
coefficient (r). A P-value of <0.05 was considered
significant.Table I
Characteristics of all patients with knee OA and the subgroup of
female patients
Characteristic All patients
(N=196)
Female
patients
(N=153)
Age, mean (range) years 62 (44–76) 60 (44–76)
OA duration, mean (range) years 10 (1–50) 10 (1–40)
ISK*, mean (range) 9 (3.5–13) 9 (4–13)
Knee OA, number (%)
Unilateral 40 (20%) 27 (18%)
Bilateral 156 (80%) 126 (82%)
Kellgren–Lawrence grade,
number (%)
I 38 (19%) 34 (22%)
II 87 (44%) 71 (46%)
III 63 (32%) 42 (27%)
IV 8 (4%) 6 (4%)
Knee synovitis, number (%)
Total 133 (68%) 106 (69%)
Unilateral 102 (52%) 81 (53%)
Bilateral 31 (16%) 25 (16%)
*ISK=The Index of Severity for Knee OA according to Lequesne
et al.30.Table II
Serum COMP levels for all OA patients by OA severity and
synovitis*
Group N COMP level, mean
(95% CI)
Total 196 1.087 (1.038, 1.137)
K–L ≤2 125 1.029 (0.973, 1.088)
K–L >2 71 1.197 (1.112, 1.289)†
Syn (−) 63 1.007 (0.934, 1.085)
Syn (+) 133 1.127 (1.065, 1.192)‡
K–L ≤2, Syn (−) 44 0.994 (0.908, 1.089)
K–L ≤2, Syn (+) 81 1.048 (0.975, 1.126)
K–L >2, Syn (−) 19 1.036 (0.896, 1.199)
K–L >2, Syn (+) 52 1.262 (1.160, 1.372)
*Values for COMP levels are expressed in g/ml.
Syn (−)=synovitis absent clinically; Syn (+)=synovitis present
clinically.
†P<0.01 compared with K–L ≤2.
‡P<0.05 compared with Syn (−).Results
Clinical and radiographic data were obtained at the time
of sera collection on 196 patients. The patients were
predominantly female with bilateral knee OA (Table I). The
most severely diseased knee was used for purposes of
grading, when bilateral knee OA of different grades was
present. This occurred in 51 of the 156 bilateral knee OA
cases and in 39 of the bilateral knee OA cases in the
female subgroup. Synovitis at the time of sera collection
was present in 68% of patients and was slightly more
prevalent in the more severely affected OA knees (synovitis
in 74% of K–L grade >2) compared with the less severely
affected OA knees (synovitis in 65% of K–L grade ≤2).
Although a total of 51 cases of bilateral knee OA demon-
strated more severe OA in one knee compared with the
other, the majority of clinically detected synovitis occurred
in the more severely affected knee (44 of 51 cases or 86%).
Table II summarizes unadjusted serum COMP levels by
OA severity and presence of synovitis. COMP levels were
higher in the group with K–L grade >2 knee OA (1.197 g/ml) compared with the group with less severe K–L grade ≤2
OA (1.029 g/ml) (P=0.002 by two-way ANOVA using ln
transformed COMP). COMP levels were also higher in the
group with synovitis (1.127 g/ml) compared with the group
lacking synovitis (1.007 g/ml) (P=0.038).
The effect of age, gender, and interaction of age and
gender on ln(COMP) was tested by multiple regression.
The multiple correlation coefficient was 0.482 (P<0.001).
The effect of age on ln(COMP), when tested by means of
linear regression, was different for males (correlation coef-
ficient 0.121, NS) and females (correlation coefficient
0.524, P<0.001) (Fig. 1). Non-parallelism of both gender
groups was highly significant (P<0.001). Thus, age and
gender have to be considered confounding variables with
regard to serum COMP levels.
Since the proportion of females recruited into the study
was much higher than that of males, and since the charac-
teristics of the subgroup of female patients were similar to
the characteristics of the group as a whole (Table I), we
Osteoarthritis and Cartilage Vol. 9, No. 7 615chose to analyse the subgroup of female patients in more
detail. Table III summarizes serum COMP levels in the
subgroup of 153 female OA patients by radiographic grade
knee OA and by knee synovitis. Unadjusted COMP levels
were highest in the cases with more severe OA (K–L grade
>2) and synovitis (P=0.001 and P=0.03, respectively).
However, after adjusting for age, only the increase by
synovitis remained significant (P=0.017).
The effects of synovitis, K–L grade, age, duration of the
disease, ISK value, and CRP level on ln(COMP) for the
subgroup of female patients was tested by multiple regres-
sion. The results are summarized in Table IV. Besides age,
serum COMP was influenced by synovitis and by an
interaction of synovitis and K–L grade. K–L grade alone
however was not significantly correlated to ln(COMP) lev-
els whereas synovitis alone was significant, showing the
strongest effect of all the variables examined with a regres-
sion coefficient of 0.1587 (P<0.01). There was no signifi-
cant effect of CRP level, ISK or disease duration on
ln(COMP). The effect of three clinical signs of synovitis (T,
S, and W) on ln(COMP), was tested for the subgroup of
female patients using two independent models of linear
regression, including age as a confounding variable. For
each patient, the indices of synovitis were summed across
both knees to give a total grade for T, S, and W. The simple
regression model was used for sum of grades of all three
signs (T+S+W); the multiple regression model was used to
test for the effect of three signs separately (Table V). The
linear regression model was significant for: (i) sum of total
grades of all three signs (T+S+W); (ii) total grade of
tenderness (T); (iii) total grade of warmth (W). The effect
of the total grade of swelling (S) was not significant. The
sum of grades of all three clinical signs of syno-
vitis (T+S+W) did not correlate significantly with CRP
level (P=0.079), when compared using the Spearman
correlation coefficient.–1.0
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Fig. 1. An effect of age on COMP levels [expressed as ln(COMP)]
measured by ELISA with mAb 17-C10 in sera of OA patients.
()—observed values, females; ()—observed values; males.
Best-fit regression lines were calculated independently for female
(——) and male (– – –) patients using linear regression model.Discussion
We have detected significant differences in unadjusted
serum COMP levels, measured by ELISA with mAb
17-C10, between groups of patients with knee OA sorted
according to radiographic grade (K–L grade ≤2 vs K–L
grade >2) or according to the presence of clinicallydiagnosed synovitis of the knee. However, we have identi-
fied age as a confounding variable. After adjusting for age
in the subgroup of female patients, only the effect of
synovitis on COMP level remained statistically significant.
Thus, our study demonstrates a correlation of clinically
evident synovitis with serum COMP. Although the differ-
ences reported are statistically significant, they are small in
terms of actual numerical difference. There is overlap
between individual groups differentiated by synovitis thus
serum COMP cannot be used as a discriminating test in
individuals.
We used two assays to measure blood CRP level. We
were concerned that the turbidimetric assay might not be
sensitive enough to detect small elevations in CRP level
associated with low-grade inflammation accompanying OA
and detected by high-sensitivity immunoassays as was
described recently35,36. Thus we also measured CRP lev-
els by a very sensitive sandwich ELISA assay. Although
blood CRP levels determined by the two different methods
correlated highly, neither of them correlated to blood COMP
levels or to clinical indicators of knee inflammation. We
suggest that serum COMP probably reflects local,
OA-associated inflammation localized to a joint, while CRP
reflects a systemic inflammatory response, like general
infection.
Using a larger sample size and the same mAb to COMP,
we have previously observed higher serum COMP levels in
individuals with knee OA of K–L grade ≤2 compared to a
control population without knee or hip OA29. However, in
the present study, the difference in serum COMP levels
between two groups with knee OA (mild and severe) was
not large enough to be statistically significant although the
same trend was apparent, with higher mean serum COMP
in the more severely affected group. Both studies have
shown that serum COMP level increases with age, but this
effect is more pronounced in females than in males. The
difference between female and male subjects may relate to
post-menopausally increased bone metabolism character-
ized by up-regulated osteoclastic and osteoblastic activity,
since, according to a recent finding37, COMP is also
expressed by osteoblasts.
Although the study populations in these two studies (this
and Clark et al.29) were very different, one a rural popula-
tion in North Carolina, the other an urban population in
middle Europe (both Caucasian), the 17-C10 ELISA
measured very similar levels of serum COMP. This agree-
ment was achieved by using the same mAb to COMP in
addition to the same standard of human cartilage COMP in
both studies. Although an internationally recognized COMP
standard is not available, the advent of mAbs for COMP
may aid in the standardization of COMP assays whose
feasibility is demonstrated here. Compared to studies that
measured COMP by ELISA with polyclonal antibodies13–18,
we report lower (by approximately 10-fold) levels of serum
COMP. There are several possible explanations of this
difference; the 17-C10 mAb may detect a narrower range of
serum COMP fragments than is detected by polyclonal
antibodies, and the purity of our standard may be greater,
yielding overall lower COMP values.
Synovium is known to produce COMP21–25 and in theory
may contribute measurable levels of COMP to the serum.
We have detected measurable amounts of COMP in hyper-
trophic synovium collected at the time of knee surgery from
three OA patients28. The concentration of COMP in these
synovial specimens, determined by ELISA with mAb
17-C10, ranged from 4 to 64 g/g wet weight of tissue.
Neidhart et al.38 detected COMP at concentrations of
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Serum COMP levels for subgroup of female OA patients by OA severity and synovitis*
Group N COMP level, mean (95% CI)
Unadjusted Adjusted for age
Total 153 1.066 (1.012, 1.123) 1.066 (1.020, 1.115)
K–L ≤2 105 1.004 (0.946, 1.065) 1.049 (0.996, 1.105)
K–L >2 48 1.217 (1.106, 1.340)‡ 1.104 (1.014, 1.203)NS
Syn (−) 47 0.979 (0.897, 1.069) 0.985 (0.912, 1.064)
Syn (+) 106 1.107 (1.039, 1.180)† 1.105 (1.047, 1.165)†
K–L ≤2, Syn (−) 35 0.963 (0.873, 1.063) 1.019 (0.935, 1.111)
K–L ≤2, Syn (+) 70 1.025 (0.951, 1.104) 1.065 (0.997, 1.137)
K–L >2, Syn (−) 12 1.028 (0.830, 1.272) 0.891 (0.745, 1.066)
K–L >2, Syn (+) 36 1.288 (1.158, 1.433) 1.186 (1.083, 1.298)
*Values for COMP levels are expressed in g/ml.
Syn (−)=synovitis absent clinically; Syn (+)=synovitis present clinically.
NSNot significant compared with K–L ≤2.
†P<0.05 compared with Syn (−).
‡P<0.01 compared with K–L ≤2.Table IV
An effect of various factors on ln(COMP): multiple regression
model for female OA patients
Factor b 95% CI
Age 0.022 (0.015, 0.280)***
Synovitis 0.159 (0.051, 0.267)**
K–L grade −0.007 (−0.123, 0.110)NS
Interaction of K–L grade and
Synovitis 0.116 (0.011, 0.222)*
CRP 0.000 (−0.006, 0.006)NS
ISK 0.006 (−0.016, 0.026)NS
Duration of OA 0.000 (−0.007, 0.006)NS
Standard error of regression model=0.2688; multiple correlation
coefficient r=0.5619.
Synovitis: patients were sorted into two groups, i.e., synovitis
present clinically vs synovitis absent clinically (for definition of
synovitis, see Methods).
K–L grade: patients were sorted into two groups, i.e., K–L grade
≤2 vs K–L grade >2.
ISK=The Index of Severity for Knee OA according to Lequesne
et al.30.
CRP=serum level of C-reactive protein.
b=Regression coefficient.
NSNot significant; *P<0.05; **P<0.01; ***P<0.001.3.40 mg/g and 2.17 mg/g wet weight of human tibial and
femoral cartilage, respectively. It can be estimated from
these data that the concentration of COMP (per wet weight
of tissue) in synovium is about 100 times lower then the
concentration in articular cartilage. Supporting this conten-
tion, Saxne and Mansson report a similar estimation cited
as an unpublished observation15. There is no available
information at present on the turnover rate of COMP in
synovial tissue and in cartilage. These turnover rates may
vary by tissue type and by pathological condition. Dodge
et al.24 have reported that cultured human synovial cells
produce more COMP (per g DNA) than cultured articular
chondrocytes maintained under conditions which promote
retention of a cartilage-specific phenotype. DiCesare
et al.25 have found that COMP mRNA levels are three-fold
higher in rheumatoid synovium compared to osteoarthritic
synovium; the authors concluded from this comparison that
inflammatory synovium should be considered a potential
source of serum COMP. It has also been shown that apro-inflammatory cytokine, TGF-, can induce COMP
mRNA and protein in synovial fibroblasts23.
The clinical estimation of inflammation (synovitis) still
remains an unresolved problem. Some objective methods
(thermocameras, isotopes) have failed, while other modern
objective methods (MRI, ultrasound) are not validated for
clinical studies yet. Both synovial biopsy and arthroscopy
are invasive and their routine use in studies like this are
difficult to justify for ethical reasons. Therefore, the recom-
mended tools for clinical detection of synovitis are various
joint indices (tender joint count, swollen joint count). We
decided to use standard measures of tenderness, swelling,
and warmth, performed by a single rheumatologist, to make
a clinical determination of synovitis. The reproducibility of
clinically determined synovitis in this study was 80%, thus
validating the clinical relevance of our serum COMP find-
ings. The association of higher synovitis scores with higher
COMP levels might strengthen the evidence of an associ-
ation of COMP levels with synovitis. However, the associ-
ations of the three clinical signs of synovitis with serum
COMP levels were not the same. The association with
tenderness was the most pronounced while the association
with swelling was not significant (Table V). We concluded
that we could not divide patients further into subgroups
based upon various levels of the total score for further
statistical analysis in a sample of this size.
Episodic inflammation of affected joints is frequent in OA
patients and synovitis is common in patients with advanced
OA. Synovitis, defined as mononuclear cell infiltration on
synovial tissue biopsy, was found in 50% of patients with
early knee OA of K–L grade <3 by Myers et al.39, while only
38% of all their patients (i.e., 76% of patients with histologi-
cally diagnosed synovitis) would have been simultaneously
diagnosed clinically by our criteria (pain and effusion and/or
warmth), indicating that we have probably missed some
cases of inflammation, presenting with less striking clinical
symptoms.
Our results suggest that inflamed synovium may either
(1) produce COMP in amounts significant enough to be
detected in serum by immunoassay with mAb 17-C10 or (2)
accelerate cartilage loss of antigenic fragments of COMP,
or (3) affect joint clearance of cartilage-derived COMP. All
these mechanisms may operate simultaneously and all of
them may be partially responsible for the serum COMP
level increase. Our results do not necessarily suggest
extra-cartilage origin of blood COMP, as it has been shown
Osteoarthritis and Cartilage Vol. 9, No. 7 617that even mild synovitis may significantly increase the
clearance of a protein from the synovial fluid40,41. On the
other hand, COMP produced in synovium may enter
the bloodstream directly, and thus may influence serum
level more than COMP produced in cartilage, that has to
enter the bloodstream via the synovial fluid and may
therefore be subject to greater lymphatic uptake. Thus,
although the actual mechanism causing the observed effect
is unclear, synovitis should be considered a factor that
affects serum COMP levels.
In summary, in this study we have identified another
factor, besides age and OA severity, that influences the
level of serum COMP in patients with knee OA, namely
synovitis of the knee. This finding invites consideration of
the role that synovitis may play in OA progression in light of
studies showing that higher levels of serum COMP indicate
patients with faster progressing OA. These results under-
score the importance of assessing for synovitis by clinical
joint examination in future studies of OA and COMP.Acknowledgments
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An effect of three clinical signs of knee joint inflammation, tenderness (T), non-bony swelling (S), and warmth (W),
on ln(COMP): regression models for female OA patients†
Clinical sign b 95% CI b 95% CI
T+S+W 0.032 (0.012, 0.051)**
T 0.053 (0.017, 0.089)**
S −0.011 (−0.540, 0.032)NS
W 0.077 (0.017, 0.137)*
†The table describes two regression models, i.e., the simple regression model (T+S+W) used for the sum of
total grades of all three signs of synovitis, and the multiple regression model (T, S, W) used to test for the effect
of three signs of synovitis separately. Standard errors of regression models T+S+W and T, S, W equal to 0.269
and 0.267, respectively; correlation coefficient r (T+S+W) equals to 0.567; multiple correlation coefficient r (T, S,
W) equals to 0.586.
b=Regression coefficient.
NSNot significant; *P<0.05; **P<0.01.References
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